Related Experiment Video

Updated: Sep 29, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Intraperitoneal rituximab: an effective measure to control recurrent abdominal ascites due to non-Hodgkin's lymphoma

T Ng1, A Pagliuca, G J Mufti

  • 1Department of Haematological Medicine, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom. tsfng@hotmail.com

Annals of Hematology
|August 20, 2002
PubMed

We report a patient with an advanced stage low-grade small lymphocytic lymphoma who required regular drainage of malignant ascites for symptomatic relief despite intensive treatment. The administration of rituximab via the intraperitoneal route successfully controlled the ascites. The patient tolerated well with this unusual route of administration and has not required any further ascitic drainage for at least 8 months. In view of its simplicity, good tolerability and effectiveness to control recurrent ascites secondary to low-grade non-Hodgkin's lymphoma (NHL), this novel route of administration of rituximab is worth exploring.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...